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Background: Chemotherapy for soft tissue sarcomas remains unsatisfactory due to their low chemosensitivity. Even
the first line chemotherapeutic agent doxorubicin only yields a response rate of 18-29%. The antibiotic salinomycin,
a potassium ionophore, has recently been shown to be a potent compound to deplete chemoresistant cells like
cancer stem like cells (CSC) in adenocarcinomas. Here, we evaluated the effect of salinomycin on sarcoma cell lines,
whereby salinomycin mono- and combination treatment with doxorubicin regimens were analyzed.
Methods: To evaluate the effect of salinomycin on fibrosarcoma, rhabdomyosarcoma and liposarcoma cell lines,
cells were drug exposed in single and combined treatments, respectively. The effects of the corresponding
treatments were monitored by cell viability assays, cell cycle analysis, caspase 3/7 and 9 activity assays. Further we
analyzed NF-κB activity; p53, p21 and PUMA transcription levels, together with p53 expression and serine 15
phosphorylation.
Results: The combination of salinomycin with doxorubicin enhanced caspase activation and increased the sub-G1
fraction. The combined treatment yielded higher NF-κB activity, and p53, p21 and PUMA transcription, whereas the
salinomycin monotreatment did not cause any significant changes.
Conclusions: Salinomycin increases the chemosensitivity of sarcoma cell lines - even at sub-lethal concentrations -
to the cytostatic drug doxorubicin. These findings support a strategy to decrease the doxorubicin concentration in
combination with salinomycin in order to reduce toxic side effects.
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Soft tissue sarcomas are a rare and heterogeneous entity
of tumors with an annual incidence of 2-4/100,000 [1].
In contrast to carcinomas, soft tissue tumors are of mes-
enchymal origin. According to the tumor grading the 5-
year survival ranges from 72-83% in well differentiated
G1 sarcomas, 53-59% in G2 sarcomas to 26-42% in G3
sarcomas [2]. Metastatic disease becomes evident within
the first 2–3 years after initial diagnosis and is the main
cause of mortality in these patients [3]. Despite multi-
disciplinary treatment (i.e. surgery, chemotherapy and
radiation therapy), the rate of recurrence remains higher
than 50%, and results in diffuse metastatic disease and* Correspondence: sven-thorsten.liffers@rub.de
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reproduction in any medium, provided the orthe death of the patients [4]. Chemotherapy for advanced
tumors remains unsatisfactory due to low chemosensitivity
despite combination chemotherapeutics. The most effect-
ive chemotherapeutic agents are the anthracyclines doxo-
rubicin and epirubicin [5-7]. Doxorubicin still remains the
first line chemotherapeutic for soft tissue sarcomas. Un-
fortunately, its cytostatic effect in therapeutic doses is fre-
quently insufficient (monotherapy response rate of only
18-29%); but the use of higher doxorubicin doses is lim-
ited by the development of systemic toxicity, especially
cardiotoxicity. In addition to the poor response rate to
doxorubicin, the development of drug resistance remain
an unresolved problem [8-12].
The anionic and weakly acidic antibiotic salinomycin
acts in different biological membranes including cy-
toplasmic and mitochondrial membranes. In addition
to its antimicrobial properties, salinomycin selectivelytd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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impedes breast tumor growth in mice xenograft expe-
riments [13]. The activation of apoptotic pathways by
salinomycin is independent of p53 and caspase activation
[14]. Further, it has been reported that salinomycin sensi-
tized cancer cells by reducing p21 levels [15,16]. However,
little is known about its impact on sarcomas.
In order to improve the oncological treatment of pa-
tients with soft tissue sarcoma mechanisms to overcome
drug resistance and reduce drug toxicity must be identi-
fied. Therefore, the aim of this study was to evaluate the
effect of salinomycin on the chemosensitivity to doxo-
rubicin in three different soft tissue sarcoma cell lines.Methods
Cell culture
The human soft tissue sarcoma cell lines SW872
(liposarcoma cell line), A204 (rhabdomyosarcoma cell
line) and HT-1080 (fibrosarcoma cell linie) (ATCC-LGC
Standards, Wesel, Germany) were cultured in DMEM
(PAN-Biotech, Aidenbach, Germany) media containing
10% fetal bovine serum (Hyclone-Thermo Scientific,
Bonn, Germany) and 1% penicillin/streptomycin (PAN-
Biotech, Aidenbach, Germany) and were incubated at
37°C and 5% CO2.Cell viability assay
Cells were seeded at 2×104 per well in 24 well plates
and treated 16 h later at the indicated drug concentra-
tions. Forty-eight hours after the application of salino-
mycin (Sigma, Taufkirchen, Germany), doxorubicin (Sigma,
Taufkirchen, Germany) or both compounds together, re-
spectively, 100 μl of MTT solution (5 mg/mL) was added
per well. Cells were lysed with 250 μl triplex solution
(1 mM HCl; 5% iso-butanol; 1% SDS), after 3 h of incu-
bation. Optical density was measured at 562 nm with a
background correction at 630 nm. All data points were
normalized with respect to the DMSO control.Cytotoxicity assay
Alternatively, determination of cytotoxicity was carried
out using the MultiTox-Glo assay (Promega, Mannheim,
Germany). For this, 3000 cells per well were seeded in
96 well plates (Corning, Amsterdam, Netherlands), and
treated 16 h after cell seeding in the presence of a dose–
response of doxorubicin in the presence and absence of
1 μM Salinomycin (i.e. 751 ng/mL). Toxicity was mea-
sured after 24 h according to the manufacturer’s instruc-
tions in four independent measurements. The cytotoxicity
is expressed as the ratio of live cell fluorescence to dead
cell luminescence, relative to the vehicle control.Caspase assay
Caspase activities were measured using the Caspase Glo
3/7 and 9 assays from Promega (Mannheim, Germany),
according to the manufacturer’s instructions. The resulting
luminescence was measured with a Tecan M200 micro-
plate reader (Tecan, Crailsheim, Germany) for 10 s meas-
urement period. Values were corrected for differences in
cell numbers by simultaneously conducting a MTT assay
(Carl Roth, Karlsruhe, Germany).
Annexin V analysis
Cells were plated at 1.5×105 cells per well in a 6 well plate
16 h before treatment and treated as indicated. DMSO
served as a vehicle control. Twenty-four hours after treat-
ment, cells were harvested and apoptosis was determined
by Annexin V-Alexa 488 (Life Technologies, Darmstadt,
Germany) staining. Cells were counterstained with 0.2 μM
TO-PRO-3 iodide (Life Technologies, Darmstadt, Germany)
to discriminate between vital and dead cells. After staining
the cells were measured on a Guava HT flow cytometer
(Millipore, Schwalbach am Taunus, Germany) in triplicates.
Data analysis was carried out using the Express Pro 2.0 soft-
ware (Millipore, Schwalbach am Taunus, Germany).
Cell cycle analysis
Cells were plated at 1.5×105 cells per well in a 6 well plate
16 h before treatment. Cells were trypsinized, collected by
centrifugation, and fixed in ice-cold 70% ethanol, 48 h post
treatment. Fixed cells were collected by centrifugation and
washed once with PBS. Subsequently, the cells were stained
in PBS buffer containing 50 μg/mL propidium iodide (MP
Biochemicals, Illkirch, France), 0.1% Triton X-100 (Sigma,
Taufkirchen, Germany) and 10 U/mL RNase A (Sigma,
Taufkirchen, Germany). After incubation for 30 min at
37°C, cell cycle profiles were measured on a Guava HT flow
cytometer following data analysis using Express Pro 2.0.
Reporter NF-κB analysis
NF-κB activity was analyzed in triplicates by transfecting
5×104 HT-1080 cells with 300 ng pGL4.32[luc2P/NF-kB-
RE/Hygro] vector (Promega, Mannheim, Germany), using
X-tremeGENE (Roche, Mannheim, Germany); 10 ng pRL-
TK (Promega, Mannheim, Germany) served as transfec-
tion control. Firefly and Renilla luciferase activities were
measured 6 h and 10 h post treatment. The luciferase-
signals were measured for 10s (Tecan M2000, Crailsheim,
Germany). The Renilla signal was used for normalization.
Mean values and SEM were calculated from triplicates.
Western blot analysis
HT-1080 cells were seeded with 1×106 cells per 10 cm
dish. Sixteen hours post seeding, the cells were subjected
for 6 h to the different treatments. The isolation of nu-
clear and cytoplasmic fractions were carried out after
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hypotonic buffer (20 mM Tris–HCl, pH 7.4, 5 mM MgCl2,
1.5 mM KCl, 0.1% NP-40, 50 mM NaF, 2 mM sodium
orthovanadate, and protease inhibitors (Complete, Roche)).
Cells were subsequently disrupted by passing them several
times through a 26 ½ gauge syringe needle, followed by a
centrifugation at 800×g (5 min; 4°C). The supernatants
were further centrifuged at 10,000×g (15 min; 4°C) to re-
move insoluble pellets, and the resulting supernatants were
collected as the cytoplasmic fractions. The pellets were
resuspended in 100 μl of TKM buffer (20 mM Tris-acetate;
pH 7.4, 50 mM KCl, 5 mM MgCl2, containing protease
and phosphatase inhibitors). After centrifugation (800×g;
10 min; 4°C), the supernatants were collected like the cyto-
plasmic fractions. From each fraction, 30 μg total protein
were subjected to 4-12% BisTris-PAGE and transferred
onto PVDF membranes (Millipore, Schwalbach, Germany)
with 2 mA/cm2 for 1 h. After protein transfer membranes
were blocked in PBS-T containing 5% (w/v) skimmed milk,
for 1 h and incubated with anti-pS15 p53 antibody (Cell
Signaling, Frankfurt am Main, Germany) and anti-p53
(Clone DO-1, Sigma-Aldrich, Taufkirchen, Germany) over-
night (1:1000 in PBS-T). As loading control for the cyto-
plasmic fraction, anti-α-tubulin antibody (Sigma-Aldrich,
Taufkirchen, Germany) was used at 1:2500 dilution in
PBS-T for 1 h at room temperature whereas anti-lamin
(Cell Signaling, Frankfurt am Main, Germany) at 1:1000
served as loading control for the nuclear fraction. Mem-
branes were incubated for detection with secondary
antibodies raised against rabbit labeled with CyDye800
(Licor, Bad Homburg, Germany) and mouse labeled with
CyDye700 (Licor, Bad Homburg, Germany) for 1 h at room
temperature. Signals were detected by Odyssee Scanner
(Licor, Bad Homburg, Germany).
RNA isolation and RT-PCR
RNA was isolated using the RNeasy mini kit (Qiagen,
Hilden, Germany), according to the manufacturer’s in-
structions. To remove possible genomic contamination,
DNA digestion was performed by using the Ambion
TurboDNAse purification kit (Life Technologies, Darm-
stadt, Germany) as described in the kit’s manual. The
RNA concentration was measured with a Tecan M200
(Tecan, Crailsheim, Germany). For quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR), first-
strand cDNA was synthesized from 1 μg of total RNA
using the Applied Biosystems High Capacity cDNA reverse
transcription kit (Life Technologies, Darmstadt, Germany).
cDNA was amplified on an Eppendorf Realplex4 thermal
cycler (Hamburg, Germany) using Promega GoTaq qPCR
Master Mix. The sequence for the PCR primers are: p21:
5′-GGCGGCAGACCAGCATGACAGATT-3′ and 5′-GC
AGGGGGCGGCCAGGGTAT-3′; p53: 5′-CTAAGCGAG
CACTGCCCAAC-3′ and 5′-GGCCTCATTCAGCTCTCGGA-3′; actin: 5′-CATGCCATCCTGCGTCTGGACC-3′
and 5′-ACATGGTGGTGCCGCCAGACAG-3′, whereas
PUMA expression was analyzed using the QuantiTect
Primer Assay (Qiagen, Hilden, Germany). After an initial
activation at 94°C for 3 min, 40 cycles of 94°C for 15 s,
55°C for 30 seconds, and 72°C for 45 s. Experiments were
done in triplicates and fold changes calculated based on the
ΔΔCt method.
Statistics
Significance testing between pairs of treatments was done
by unpaired two tailed Student’s t-test using Welch’s cor-
rection if the F-test indicated a significant difference be-
tween variances. Differences were considered significant if
p < 0.05. The IC50 was estimated from the MTT absorb-
ance data, using the four parameter logistic model in R
2.15.1. The synergy between the effects of salinomycin and
Doxorubicin was determined by the combination index
(CI) based on IC50 isobologram [17]. A CI < 0.9 was con-
sidered as synergism between the two compounds
whereas 0.9 – 1.1 indicates an additive effect.
Results
Impact of salinomycin on different soft tissue sarcoma
cell lines
The heterogeneity of soft tissue sarcomas led us to investi-
gate the impact of salinomycin on soft tissue sarcoma cell
lines of different origin. The assessed cell line panel consists
of the rhabdomyosarcoma cell line A204, the fibrosarcoma
cell line HT-1080, and the liposarcoma cell line SW872.
The dose response experiment with salinomycin re-
vealed different reductions in the growth activity of the
analyzed soft tissue sarcoma cell lines A204, HT-1080 and
SW872. The strongest decrease in cell viability was with
the A204 cells which decreased from 67.8% to 43.0%. The
HT-1080 displayed a reduction to 60% for all concentra-
tions, except 0.5 μM. The SW872 cells showed less sensi-
tivity to salinomycin treatment, with a mild reduction in
cell viability ranging from 9.1% in the presence of 0.5 μM
salinomycin to 16.9% for 10 μM salinomycin (Figure 1A).
Impact of doxorubicin treatment on different soft tissue
sarcoma cell lines
The dose response experiment for the doxorubicin
monotherapy comprised of treatments with 30 ng/mL,
60 ng/mL, 125 ng/mL or 500 ng/mL doxorubicin. In
contrast to the salinomycin treatment alone, a dose re-
sponse was observed for all cell lines in the presence of
doxorubicin (Figure 1B-D).
Impact of the combined salinomycin and doxorubicin
treatment on different soft tissue sarcoma cell lines
The combined treatment with 1 μM salinomycin and dif-
ferent doxorubicin concentrations (30 ng/mL, 60 ng/mL,
Figure 1 Dose dependent changes in the viability of soft tissue sarcoma cells in the presence of salinomycin, doxorubicin, and the
combined treatment. The impact of salinomycin was analyzed at different concentrations as indicated (A). Cell viability of adherent growing
SW872 (B), A204 (C) and HT-1080 (D) cells was measured by MTT assay 48 h post doxorubicin treatment. Error bars denote the standard error
(n = 3). Student’s t-test was conducted to determine the significance (* p < 0.05, ** p < 0.01, *** p < 0.001).
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age a 1.5 fold decrease of the relative cell growth activity
in comparison to doxorubicin alone. The most significant
change was detected for HT-1080 cells at a concentration
of 125 ng/mL doxorubicin in combination with 1 μM
salinomycin, which revealed a 3-fold decrease in cell
viability compared to the corresponding doxorubicin
monotherapy (Figure 1B-D). In summary, the combined
treatment of 125 ng/mL doxorubicin with a sub-lethal
concentration of 1 μM salinomycin led to a reduction of
cell viability equal to the 4 times higher doxorubicin
monotherapy, whereas the increase of the salinomycin
concentration to 2 μM did not lead to a further decrease
in cell viability (data not shown). To further support
the observed synergistic effect between doxorubicin and
salinomycin we analyzed the ratio between viable and
dead cells by cytotoxicity assay (Figure 2). The ratio of vi-
able and dead cells in the presence of a doxorubicin dose
response in the presence and absence of salinomycin
revealed for A204 and HT-1080 cells a significant in-
crease at a doxorubicin concentration of 125 ng/mL
and higher for the combined treatment. Having shownthat the concomitant administration of doxorubicin and
salinomycin leads to a better response of the analyzed
cell lines in two independent assays, we analyzed the
potential synergistic effects by isobologram analysis
based on the IC50. The weak response of SW872 cells to
the salinomycin monotreatment does not allow for the
estimation of an IC50 for this cell line. Therefore, we ex-
cluded the SW872 cells from the isobologram analysis.
For A204 and HT-1080 cells a synergistic effect between
doxorubicin and salinomycin (Figure 3) was observed.
The calculation of the combination index (CI) revealed
that 1 μM salinomycin synergistically cooperates with
doxorubicin to decrease cell viability in both cell lines
HT-1080 (CI = 0.84) and A204 cells (CI = 0.74). A sali-
nomycin dose below 1 μM leads only in A204 cells to a
synergistic effect with doxorubicin.
Effects of salinomycin and doxorubicin on apoptosis
Given the synergistic effect of salinomycin and doxo-
rubicin on the investigated cell lines, we further eluci-
dated if the observed cell death was apoptosis related.
Therefore, we analyzed the activity of the caspases 3/7
Figure 2 Salinomycin affects the cytotoxicity of doxorubicin. Changes on cell viability were analyzed by the cytotoxicity ratio (viable/dead
cells) for SW872 (A), A204 (B) and HT-1080 (C) cells 24 h post treatment. The solid line indicates the doxorubicin monotreatment and the dashed
the combined treatment of doxorubicin with 1 μM salinomycin. Error bars denote the standard error (n = 4). Student’s t-test was conducted to
determine the significance (* p < 0.05, ** p < 0.01, *** p < 0.001).
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apoptosis. Additionally, we analyzed the early apoptotic
response of soft tissue sarcoma cells by Annexin V stain-
ing, and the sub-G1-fraction as a late event in apoptosis.
The caspase 3/7 induction was analyzed 14 h, 18 h, and
26 h post treatment by luminometric measurements
(Figure 4A-C). During the whole time course, no induc-
tion of caspase 3/7 activity was detectable in any of the
analyzed cell lines for salinomycin monotherapy,
whereas doxorubicin induced caspase 3/7 in a cell line
dependent manner. The combined treatment (i.e. 1 μM
salinomycin and 125 ng/mL doxorubicin) resulted in a
significant increase in the caspase 3/7 activity.
Next we analyzed the Annexin V+ TO-PRO-3- cell frac-
tion as an indicator of early apoptotic cells 24 h post treat-
ment (Figure 5A). The assessed cell lines showed the
highest amount of Annexin V+ TO-PRO-3- cells after theFigure 3 Salinomycin and doxorubicin synergistically effects the treat
(A) and HT-1080 (B) cells for doxorubicin in combination with salinomycincombined treatment. The observed increase of this cell
fraction was significantly higher compared to the corre-
sponding single treatments. In concordance with the cell
viability data (Figures 1 and 2) and the annexin V staining
HT-1080 and A204 cells are the most sensitive cell lines in
the flow cytometric analysis. The smallest change in the
sub-G1 fraction was observed for SW872 cells, which
showed an increase in the sub-G1 fraction of 10.7% (doxo-
rubicin monotherapy vs. combined treatment; p = 0.0052),
followed by A204 cells which showed an increase of 14.4%
(p = 0.00072). The highest increase in the sub-G1 fraction
with 28.3% was noted for the HT-1080 cells (p = 0.00088)
(Figure 5B). Our flow cytometric analysis confirmed that
the reduction noted in the cell viability data for the doxo-
rubicin monotherapy and the combination therapy related
to an increased apoptosis rate. On the other hand, no sig-
nificant increase in the sub-G1 fraction was detected afterment of soft tissue sarcoma cells. Isobologram analysis of A204
based on the IC50.
Figure 4 The combined treatment of doxorubicin and salinomycin activates caspase dependent apoptosis. Caspase assays were
conducted 14 h, 18 h and 26 h after drug administration for SW872 (A), A204 (B) and HT-1080 (C) cells. The soft tissue sarcoma cells were
cultivated with DMSO (black line), 1 μM salinomycin (green line), 125 ng/mL doxorubicin (blue line) and the combination of 1 μM salinomycin
with 125 ng/mL doxorubicin (red line). Error bars denote the standard error (n = 3). (* p < 0.05, ** p < 0.01, *** p < 0.001).
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cell lines. This indicates that in contrast to the treatment
including doxorubicin, the reduction in the cell viability
assay was not associated with apoptosis of the sarcoma
cells.
Combined treatment enhances p53 signaling in HT-1080
cells
HT-1080 cells are known for their NF-κB-mediated
chemoresistance in response to doxorubicin [18]. Hence
we focused on the regulation of NF-κB activity according
to the analyzed treatment regimens. In accordance with
the caspase assay and the sub-G1 analysis, no significantFigure 5 Salinomycin sensitizes soft tissue sarcoma cells to doxorubic
of salinomycin (1 μM); doxorubicin (125 ng/mL), or with a combination of
apoptosis events were analyzed by Annexin V+ TO-PRO-3- cell, 24 h post tr
sub-G1 cell fraction after propidium iodide staining, 48 h post treatment (B
*** p < 0.001).changes in NF-κB activity were observed in the presence
of salinomycin alone (Figure 6A). The presence of doxo-
rubicin resulted in an increase of NF-κB activity (2.6 fold
increase after 6 h and 3.7 fold increase after 10 h). Fur-
thermore, the combined treatment resulted in a signifi-
cantly higher NF-κB activation (i.e. 4.2 fold increase
after 6 h and 6.9 fold increase after 10 h), compared to
doxorubicin alone.
NF-κB has been shown to be important for the activa-
tion of p53 transcription by several agents [19,20]. These
reports in combination with the observed increased
caspase 3/7 activities in co-treated cells (Figure 4), opted
us to investigate the p53 mediated pro-apoptotic effectin induced apoptosis. Each cell line was cultivated in the presence
both compounds before cells were subjected to analysis. Early
eatment (A). DNA fragmentation was measured by flow cytometry as a
). Error bars denote the standard error (n = 3). (* p < 0.05, ** p < 0.01,
Figure 6 Impact of the combined treatment on NF-κB activity and p53 mediated apoptosis. NF-κB reporter activities in HT-1080 cells, 6 h
and 10 h post-treatment as indicated. The firefly reporter activities were normalized to Renilla luciferase (A). Real-time RT-PCR analysis of p53
(B), p21 (C) and PUMA (D) expression in HT-1080 cells following treatment for 8 h and 10 h. Actin was used for normalization. Western blot
analysis of p53 serine 15 phosphorylation 6 h after treatment (E). Lamin served as loading control for the nuclear, and tubulin for the cytoplasmic
fraction. Time course of caspase 9 activity 14 h, 18 h, 26 h after treatment as indicated (F). (* p < 0.05, ** p < 0.01, *** p < 0.001).
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and 10 h post treatment by qRT-PCR (Figure 6B). A three
times higher increase of the p53 level was detected com-
pared to the control group, whereas the doxorubicin
monotreatment led to a 2.2 fold-increase. To test if the el-
evated p53 expression correlates with the transcription of
p53 target genes, the expression of p21, a canonical p53
target, and PUMA, a pro-apoptotic gene of which the
transcription depends on p53 and NF-κB, were analyzed.A 2.6 fold increase of p21 expression for the doxorubicin
arm was detected versus a 3.1 fold increase for the com-
bined treatment option (Figure 6C). After 10 h PUMA
transcription was upregulated 6.5 fold in the combined
treatment group, whereas doxorubicin alone led only to
a 4.4 fold-increase (Figure 6D). Therefore, each of the
p53 target genes showed a time dependent increase at the
transcription level. The salinomycin monotreatment did
not reveal any fold changes exceeding a factor of 2
Liffers et al. BMC Cancer 2013, 13:490 Page 8 of 9
http://www.biomedcentral.com/1471-2407/13/490(Figure 6B-D). In addition to the changes of the transcrip-
tion level, we investigated the serine 15 phosphorylation of
p53 as an indicator of genotoxic stress. The phosphoryl-
ation state of serine 15 was analyzed 6 h post treatment.
The Western blot analysis clearly demonstrated the accu-
mulation of p53 phospho-serine 15 in the nuclear extracts
of HT-1080 cells which were subjected to either doxorubi-
cin or combined treatment. In addition the extracts of the
combined treatment displayed a stronger serine 15 phos-
phorylation (Figure 6E). In the presence of salinomycin,
doxorubicin further enhanced the phosphorylation of p53
at serine 15. This supports the hypothesis that salinomycin
sensitizes soft tissue sarcoma cells to the effects of doxo-
rubicin, rather than inducing apoptosis on its own because
salinomycin was not able to induce serine 15 phosphoryl-
ation in the absence of the genotoxic agent doxorubicin.
Finally, we analyzed the caspase 9 activation of the dif-
ferent treatment regimes. Caspase 9 activation is initiated
by PUMA which inhibits Bcl-2. The caspase 9 activity was
significantly upregulated after 18 h, and further increased
after 26 h for the combined versus the doxorubicin single
treatment (Figure 6F) which correlates well with the
Caspase 3/7 activities (Figure 4C).
Discussion
Malignant soft tissue tumors are composed of a hetero-
geneous cell population which exhibits varying degrees
of chemosensitivity. A high rate of recurrence would be
expected even if only a minor percentage of the cancer
cells with a high resistance to systemic therapy persist in
the patient [21]. This hypothesis is also reflected by the
clinical characteristics of these tumors with a marked
chemoresistance, high rate of relapse and metastasis.
The antibiotic salinomycin has been demonstrated to
overcome drug resistance in various apoptosis-resistant
human cancer cells including CSCs [13,22,23]. Further-
more, it has been shown that the cell death induced by
salinomycin occurs independent of p53 and caspase acti-
vation [14,24], pathways that are frequently disturbed in
tumors. Therefore, we studied whether salinomycin
could have a therapeutic use in sarcomas.
The sarcoma cell lines HT-1080, A204, and SW872
displayed a slight reduction of the cell growth in MTT as-
says between 0.5 μM to 10 μM, without any significant
changes at concentrations higher than 1 μM, but further
analysis revealed no increases in caspase 3/7 activity or the
sub-G1 fraction and only a minor increase in Annexin V
staining. These results indicated that at the tested concen-
tration of 1 μM salinomycin no apoptotic cellular response
occurred. In contrast, we were able to show that even at
low salinomycin doses, which did not directly provoke cell
death, salinomycin was able to enhance the cellular re-
sponse to doxorubicin. The concurrent administration of
1 μM salinomycin in combination with doxorubicin dosesranging from 30 ng/mL to 500 ng/mL showed a synergistic
effect on apoptosis. This was supported by the lowered
doxorubicin IC50 in all cell lines in the presence of sali-
nomycin. The salinomycin concentration in the present
study was 10–20 fold below the concentrations used in a
previously published study [15], and below the direct toxic
dose of salinomycin for the analyzed sarcoma cell lines.
These findings further suggest that salinomycin is acting
synergistically to doxorubicin therapy even if used at a sub-
lethal concentration. This proved that the combination is
more effective in the treatment of sarcoma cells than the
doxorubicin monotherapy on its own.
The development of multiple mechanisms of drug and
apoptosis resistance is a hallmark of soft tissue sarcomas.
For sarcoma cell lines the abrogation of p53-induced apop-
tosis by blocking NF-κB is described as a mechanism of
drug resistance [25,26], whereas HT-1080 cells acquire
chemoresistance through the activation of NF-κB to medi-
ate cell survival [18]. This demonstrates the dual function
of NF-κB in the regulation of pro- and anti-apoptotic cellu-
lar responses. In this study we observed that the activity of
NF-κB is higher in cells which were simultaneously treated
with doxorubicin and salinomycin than in the doxorubicin
monotherapy. Therefore we propose that in the presence
of 1 μM salinomycin, the NF-κB signaling induced by
doxorubicin is shifted towards a pro-apoptotic response ra-
ther than cell survival in HT-1080 cells. NF-κB has been
proposed to be a transcription factor of p53 [27,28]. This
led us to analyze the canonical p53 targets PUMA and
p21. PUMA plays a pivotal role in p53 dependent and
independent apoptosis. Normally expressed at low con-
centrations, PUMA is markedly induced following DNA
damage. This is further supported by the strong increase of
PUMA at the transcription level 10 h after drug adminis-
tration, whereas the p21 induction is only slightly different
from doxorubicin monotreatment. In addition to the p53
dependent induction, Wang et al. reported that PUMA
expression can also be induced directly by NF-κB inde-
pendent of p53 signaling [29]. The significant increase of
PUMA expression by the combined treatment is further
supported by the stronger activation of caspase 9, a canon-
ical downstream effector of PUMA. Therefore our data
support a model in which a sub-lethal dose of salino-
mycin in combination with doxorubicin enables the pro-
apoptotic function of NF-κB and enhances the activation
of PUMA-mediated apoptosis. Furthermore, Liu et al.
reported that PUMA is also important in p53-dependent
apoptosis for the depletion of adult stem cells [30].
Conclusion
Now that salinomycin has been shown to be efficient in
soft tissue sarcomas in vitro, the study of its safety, tox-
icity, pharmacology and anticancer activity in vivo will
be the next step. In conclusion, this study demonstrated
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therapy on sarcoma cell lines and permits lower-dose
doxorubicin therapy potentially reducing the develop-
ment of its systemic toxicity. Salinomycin may be a valu-
able chemotherapeutic adjuvant in the treatment of soft
tissue sarcoma patients.
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